

1 **Novel antibiotic resistance genes from the hospital effluent** 2 **are disseminated into the marine environment in Norway**

3

4 Vera Radisic^{1,2†}, Manish, P. Victor^{1†}, Didrik H. Grevskott¹, Nachiket P. Marathe^{1#}

5

6 ¹Department of Contaminants and Biohazards, Institute of Marine Research (IMR), Bergen,
7 Norway

8 ²Department of Biological Sciences, University of Bergen (UiB), Bergen, Norway

9 Vera Radisic and Manish, P. Victor contributed equally to this work.

10

11 # Correspondence can be addressed to Nachiket P. Marathe, nachiket.marathe@hi.no

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

30 Abstract

31 Hospital effluent comprises feces of many individuals, including patients undergoing
32 antibiotic treatment. Although, hospital effluent is an important source for contamination of
33 the environment with antibiotic resistance genes (ARGs) and pathogens, how hospital
34 effluent in a low resistance setting contributes to antimicrobial resistance (AMR) in the
35 environment is largely understudied. The aim of our study was to understand the microbiota
36 and resistome of hospital effluent, and its role in the spread of AMR in the marine
37 environment in Norway. We further aimed at describing/characterizing novel resistance
38 factors from hospital effluent and the receiving sewage treatment plant (STP). 24-hour
39 composite samples of the hospital effluent and the influent and effluent of the receiving STP
40 were collected at two sampling time-points (February and April 2023) in Bergen city,
41 Norway. Isolation of *Escherichia coli* and *Klebsiella* spp. was performed, using ECC and
42 SCAI plates with cefotaxime, tigecycline or meropenem, followed by antibiotic susceptibility
43 testing, using EUVSEC3 plates. Whole-genome sequencing of selected strains (n=36) and
44 shotgun metagenomics of sewage samples (n=6) were performed, using Illumina NovaSeq.
45 ARGs were identified with USEARCH, and known and novel ARGs were assembled with
46 fARGene. All *E. coli* strains (n=66) were multidrug-resistant (MDR), while 92.3% of the
47 *Klebsiella* spp. strains (n=55) showed MDR phenotype. The sequenced strains carried
48 multiple clinically important ARGs, including carbapenemases such as NDM-5 (n=3) and
49 KPC-3 (n=3). We obtained 238 Gigabases of sequence data from which we identified 676
50 unique ARGs with >200 ARGs shared across samples. We assembled 1,205 ARGs using
51 fARGene, 365 gene sequences represented novel ARGs (< 90% amino acid (aa) identity).
52 Both known and novel ARGs (n=54) were shared between the hospital effluent and the
53 treated effluent of the receiving STP. We show that hospital effluent in Norway has a high
54 diversity of both known and novel ARGs. Our study demonstrates that hospital effluent is a
55 source of clinically relevant pathogens, as well as known and novel ARGs, reaching the
56 marine environment in Norway through treated sewage.

57

58

59

60

61

62

63

64

65

66

67 **Keywords:** Norway; Hospital effluent; Antibiotic resistance genes; fARGene; Novel ARGs;
68 Last resort antibiotics

69

70

71

72

73

74

75 **1. Introduction**

76 Antimicrobial resistance (AMR) is an emerging global health problem (WHO, 2017).
77 Pathogens of particular concern to the public health include extended spectrum β -lactamases
78 (ESBL)- and carbapenemase-producing *Enterobacterales* (WHO, 2017). Carbapenems are
79 last resort antibiotics used for treatment of severe infections cause by multidrug-resistant
80 (MDR) pathogens (Sheu et al., 2019; Zhu et al., 2020). Resistance to carbapenems is largely
81 due to the presence of carbapenem hydrolyzing β -lactamases or carbapenemases (Sheu et al.,
82 2019; Tamma & Simner, 2018). The five clinically most relevant carbapenemases are KPC,
83 IMP, VIM, NDM and OXA-48 variants (Bonnin et al., 2021). KPC belongs to Ambler class
84 A, while IMP, VIM and NDM belongs to class B (metallo- β -lactamases (MBLs)) and OXA-
85 48 variants belong to class D of β -lactamases (van Duin & Doi, 2017). MBLs are of
86 particular concern as they hydrolyze most β -lactam antibiotics, and have successfully being
87 disseminated globally (Boyd et al., 2020; Logan & Bonomo, 2016). Although, the use of
88 carbapenems in clinics is low in Norway, the prevalence of carbapenemase-producing clinical
89 strains has increased over the past few years (NORM/NORM-VET, 2023).

90

91 Pathogens, antibiotic resistance genes (ARGs) and residues of antibiotics may be introduced
92 into the environment through different routes, such as pollution with untreated sewage from
93 the population, industries and/or hospitals (Stalder et al., 2012). The hospital effluent, in
94 particular, is an important source of clinically relevant pathogens, ARGs and residues of
95 antibiotics reaching the receiving environment (Karkman et al., 2019; Khan et al., 2021;
96 Marathe et al., 2019). Hospital effluent contains fecal material from many individuals
97 undergoing antibiotic treatment, and invariably contains antibiotic resistant bacteria, resistant
98 genes, as well as residues of different antimicrobial compounds (Deguenon et al., 2022; Orias
99 & Perrodin, 2013). Hospital effluents are treated on-site in some countries, but not in Norway
100 (VKM, 2020). How untreated hospital effluent contributes to the spread of AMR in the
101 receiving STP and eventually to the marine environment in Norway is largely unknown.

102

103 The aim our study was to understand the microbiota and resistome of hospital effluent and its
104 role in the spread of AMR in the marine environment in Norway. We further aimed at
105 describing/characterizing novel resistance genes from hospital effluent and the receiving
106 sewage treatment plant (STP).

107

108 **2. Materials and Methods**

109 **2.1 Collection of sewage samples**

110 Composite samples, representing a 24-hour period, from both raw sewage (influent) and
111 treated sewage (effluent) were collected on two occasions (February 7th and April 12th, 2023)
112 from the second largest sewage treatment plant (STP), Holen, in Bergen, Norway. This
113 treatment plant, serving 132,000 inhabitants, receives sewage from two hospitals: a 933-bed
114 and a 170-bed hospital. Moreover, composite sewage samples were also collected directly
115 from the sewer line from the Haukeland University hospital in Bergen, on the same two
116 occasions. The sewage samples were transported to the laboratory in sterile containers at 4°C,
117 and analyses were initiated within 6 h after collection.

118

119 **2.2 Isolation and identification of pathogens**

120 The samples were serially diluted ten-fold with sterile saline (0.85% NaCl) before plating on
121 ECC (CHROMagar™, France) chromogenic media and on Simmons Citrate Agar with myo-
122 Inositol (SCAI) (Sigma-Aldrich, Germany) media supplemented with three different
123 antibiotics: 2 mg/L cefotaxime (Sigma-Aldrich, Germany), 0.5 mg/L tigecycline (Glentham
124 Life Sciences, UK), or 0.125 mg/L meropenem (Sigma-Aldrich, Germany). The ECC plates
125 were incubated at 37°C for 20-24 h, while the SCAI plates were incubated 37°C for 24-48 h.
126 *E. coli* CCUG 17620 and *K. pneumoniae* CCUG 225T were included as negative controls for
127 verifying the ECC and SCAI plates, respectively. From each sample, 10-15 isolated colonies
128 were picked depending on growth, restreaked and incubated at 37°C overnight. Identification
129 of strains was performed, using matrix-assisted laser desorption ionization-time of flight mass
130 spectrometry (MALDI-TOF MS) (Bruker Daltonics, Germany) at the Institute of Marine
131 Research (IMR, Norway). Subsequently, confirmed strains were stored at -80°C in Mueller-
132 Hinton (MH) broth (Oxoid, UK) with respective antibiotics and 20% glycerol until further
133 use.

134

135 **2.3 Antibiotic sensitivity testing**

136 The resistance profile of 66 *E. coli* and 55 *Klebsiella* spp. strains were determined against 15
137 antibiotics, using a broth microdilution assay with Sensititre® EUVSEC3 plates (Thermo
138 Scientific, USA), following manufacturer's protocol. The plates were incubated at 37°C for
139 20-22 h. The strains were defined as 'susceptible' or 'resistant', according to the EUCAST
140 clinical breakpoints tables v.13.1 (EUCAST, 2023). For certain antibiotics, like azithromycin,
141 nalidixic acid, sulfamethoxazole and tetracyclines, not having defined breakpoints in
142 EUCAST, resistance was determined if growth was observed in the highest antibiotic
143 concentration tested. *E. coli* CCUG 17620 was included as negative controls, while *E. coli*
144 CCUG 73937 was included as positive controls (Grevskott et al., 2020).

145

146 **2.4 DNA extraction and sequencing**

147 Based on phenotypic resistance profiles, 19 presumptive *E. coli* and 17 presumptive *K.*
148 *pneumoniae* strains were selected for whole genome sequencing (WGS). These isolates were
149 grown overnight on MH agar (Oxoid, UK) containing 2 mg/L cefotaxime (Sigma-Aldrich,
150 Germany), 0.5 mg/L tigecycline (Glentham Life Sciences, UK), or 0.125 mg/L meropenem
151 (Sigma-Aldrich, Germany), based on the resistance profiles, at 37°C. Genomic DNA was
152 extracted from the strains, using the DNeasy Blood and Tissue kit (Qiagen, Germany)
153 following the manufacturer's protocol. The extracted DNA was quantified, using Qubit™ 2.0
154 Fluorometer with the dsDNA BR (Broad-Range) kit and NanoDrop™ 2000
155 Spectrophotometer (Thermo Scientific, USA) assay. Sequencing libraries was prepared, using
156 Nextera DNA Flex Library Prep kit (Illumina, USA). Sequencing was performed, using
157 Illumina NovaSeq platform (Illumina, USA), with 2 × 150 bp on a S4 flow cell, at Eurofins
158 Genomics A/S Germany.

159

160 **2.5 Genome assembly and sequencing analysis**

161 Obtained raw reads from the Illumina NovaSeq sequencing were quality trimmed and
162 assembled as previously described (Radisic et al., 2020), follow by annotation using National
163 Center for Biotechnology Information (NCBI) Prokaryotic Genomes Automatic Annotation
164 Pipeline (PGAAP) (Tatusova et al., 2016). Antibiotic resistance genes (ARGs) and sequence
165 types (STs) of *Klebsiella* spp. were screened, using Kleborate v.2.1.0 (Lam et al., 2021),
166 while the PubMLST database (https://pubmlst.org/bigsubdb?db=pubmlst_escherichia_seqdef)
167 was used for identification of STs among *E. coli* strains. ResFinder v.4.1 (Bortolaia et al.,
168 2020) and the comprehensive antibiotic resistance database (CARD) v.3.1.4 (Alcock et al.,
169 2020) were used for further identification of ARGs among strains of *Klebsiella* spp. and *E.*
170 *coli*. PlasmidFinder v.2.1 was used for identification of plasmid replicons (Carattoli et al.,
171 2014).

172

173 **2.6 Sampling, DNA extraction and shotgun sequencing**

174 From each sample, 30-50 mL was vacuum-filtered through S-Pak filters (pore size 0.22 µm)
175 (Millipore, USA), after which the filters were transferred to 50 mL Falcon tubes and stored at
176 -20°C until further use. Genomic DNA was extracted from the filters, using DNeasy
177 PowerWater kit (Qiagen, Germany) following the manufacturer's protocol. The extracted
178 DNA was quantified, using dsDNA BR (Broad-Range) assay kit on the Qubit™ 2.0
179 Fluorometer and NanoDrop™ 2000 Spectrophotometer (Thermo Scientific, USA) assay.
180 Sequencing libraries for the shotgun metagenomics were prepared, using Nextera DNA Flex
181 Library Prep kit (Illumina, USA) and sequencing was performed, using Illumina NovaSeq
182 platform (Illumina, USA), with 2 × 150 bp chemistry on a S4 flow cell, at the Norwegian
183 Sequencing Centre (Oslo University Hospital, Ullevål, Oslo, Norway).

184

185 **2.7 Sequence analysis of shotgun metagenomic data**

186 The sequences were quality-trimmed with Trim Galore v.0.6.10
187 (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/), using the default settings;
188 `trim_galore --quality 30 --phred33 --trim_n --cores 50 --paired seqForward.fq seqReverse.fq`
189 with a phred quality score of 33 and a maximum error rate of 0.5. The quality-processed
190 reads from the metagenomes were mapped against protein sequences from a high-quality and
191 manually curated database of ARGs, mobile genetic elements (MGEs), biocide/metal
192 resistance genes (BMRGs) and virulence genes, using USEARCH
193 v.usearch11.0.667_i86linux64 with the default settings; `usearch -usearch_global reads.fastq -`
194 `db DB_seq.fasta -id 0.9 -query_cov 1.0 -blast6out hits.b6 -strand plus -maxaccepts 1`. The
195 database for BMRGs were obtained from Pal et al. (2014), virulence factors (experimentally
196 verified) from Chen et al. (2016), MGEs from Pärnänen et al. (2018), while for the ARGs
197 database we used a combination of the NCBI AMR database
198 <https://www.ncbi.nlm.nih.gov/pathogens/antimicrobial-resistance/>, CARD (Alcock et al.,
199 2020), and Antibiotic Resistance Gene-ANNOTation (ARG-ANNOT) (Gupta et al., 2014).
200 For quantitative taxonomic distribution, quality-filtered shotgun reads were used as input to
201 extract the reads corresponding to small subunit (SSU) 16S bacterial ribosomal RNA (rRNA)
202 genes from the metagenomes and assigned them to different taxonomic groups, using
203 Metaxa2 v.2.2.3 (Bengtsson-Palme et al., 2015) with the default settings; `metaxa2 -o`
204 `metaxa_out -1 (sequence1) -2 (sequence2) -f fastq -g ssu --mode metagenome --usearch`

205 v11.0.667_i86linux64 --usearch_bin usearch11 --cpu 25 --table T --reltax T and metaxa2_ttt
206 -i (taxonomy_text_file) -o metaxa_ttt_out. fARGene was used to predict probable ARGs for
207 β -lactamases (class A, subclass B1-B3, class C and D1-2), quinolones, tetracyclines,
208 macrolides, and aminoglycosides. Known and novel ARGs were assembled from shotgun
209 sequence data, using fARGene as previously described by Berglund et al. (2019) with the
210 default settings; Fargene --infile1 (sequence1) (sequence2) --hmm-model (model_name) --
211 meta --output (folder_out) --force --processes (cpu) --rerun --amino-dir class_a_out tmpdir --
212 orf-finder'. ARGs in different samples were clustered at 100/95/90% amino acid (aa)
213 sequence similarity together with previously characterized ARGs with USEARCH. The
214 query (obtained fARGenes) was blasted against nucleotide non-redundant (nr) database
215 (<https://ftp.ncbi.nlm.nih.gov/blast/db/FASTA/>) with query coverage of > 90% and E-value =
216 10^{-5} , using diamond v.2.1.9 (<https://github.com/bbuchfink/diamond>). Novel ARGs were
217 identified, using cutoff < 90% aa identity (Inda-Díaz et al., 2023). The number of shared
218 ARGs, both known and novel, across samples were clustered at 100% identity for each
219 sample and then presented in a Venn diagram, using pyvenn
220 (<https://github.com/tctianchi/pyvenn>).
221

222 **3. Results**

223 **3.1 Strains obtained from media with antibiotics**

224 Most *Klebsiella* spp. isolates and *E. coli* isolates were obtained from the hospital effluent
225 samples (n=31; n=31), followed by STP influent samples (n=19; n=21) and STP treated
226 effluent samples (n=10; n=14). In total, 130 isolates were obtained on both ECC plates with
227 antibiotics (n=66) and SCAI plates with antibiotics (n=64) and identified with MALDI-TOF
228 MS. Most of the obtained isolates on the SCAI plates (n=64) were identified as *K.*
229 *pneumoniae* (n=34, 53.1%), followed by *K. oxytoca* (n=21, 32.8%), *Raoultella*
230 *ornithinolytica* (n=5, 7.8%), *Acinetobacter bereziniae* (n=2, 3.1%), *A. baumannii* (n=1, 1.6%)
231 and *Citrobacter freundii* (n=1, 1.6%). Isolates identified as other genera than *K. pneumoniae*,
232 *K. oxytoca* and *E. coli* were not included in further analysis.
233

234 **3.2 Resistance rates in *E. coli* and *Klebsiella* spp. strains**

235 We obtained a total of 64 *E. coli* isolates on cefotaxime-containing plates and two *E. coli*
236 isolates on meropenem-containing plates. All *E. coli* isolates (n=64) on cefotaxime-
237 containing plates were multidrug-resistant (MDR), showing resistance against at least three
238 different classes of antibiotics (Supplementary Table S1). *E. coli* isolates obtained on
239 cefotaxime-containing plates from the hospital effluent samples (n=31) showed highest
240 resistance against ampicillin (100%), ceftazidime (100%), nalidixic acid (71%) and
241 ciprofloxacin (71%). Colistin resistance was detected in one *E. coli* isolate (3.2%). Further,
242 *E. coli* isolates (n=20) obtained on cefotaxime-containing plates from STP influent samples
243 showed highest resistance against ampicillin (100%), trimethoprim (81%) and
244 sulfamethoxazole (76%). Highest resistance against ampicillin (100%), nalidixic acid (79%),
245 ceftazidime (45%) and tetracycline (45%) was observed in *E. coli* isolates (n=13) on
246 cefotaxime-containing plates from STP effluent samples. *E. coli* isolates (n=2), obtained from
247 both STP influent (n=1) and STP effluent samples (n=1) on meropenem-containing plates,
248 were MDR (Supplementary Table S1). Several *E. coli* isolates from hospital effluent

249 (February: n=3; April: n=5) and STP influent (February: n=4) samples on cefotaxime-
250 containing plates displaying reduced susceptibility against meropenem. No resistance was
251 observed against tigecycline in these isolates.

252
253 On the cefotaxime-containing plates we obtained a total of 31 *Klebsiella* spp. isolates (n=21
254 hospital effluent; n=10 STP influent; n=10 STP effluent). All *Klebsiella* spp. isolates on
255 cefotaxime-resistant were MDR (Supplementary Table S1). *Klebsiella* spp. isolates (n=21)
256 obtained on cefotaxime-containing plates from the hospital effluent samples showed highest
257 resistance against ampicillin (100%), cefotaxime (100%), nalidixic acid (100%) and
258 ciprofloxacin (100%). Resistance against colistin and tigecycline was observed in 9.5% and
259 57.1% of the isolates, respectively. Further, *Klebsiella* spp. isolates (n=10) obtained on
260 cefotaxime-containing plates from STP influent samples showed highest resistance against
261 ampicillin (100%), cefotaxime (100%), ceftazidime (100%) and trimethoprim (100%).
262 Highest resistance against ampicillin (100%), cefotaxime (100%), ceftazidime (100%), and
263 sulfamethoxazole (100%) was observed in *Klebsiella* spp. isolates (n=10) on the cefotaxime-
264 containing plates from STP effluent samples. During the two-sampling time-points no
265 resistance against meropenem or amikacin was detected among these *Klebsiella* spp. isolates.

266
267 We further detected 11 *K. pneumoniae* isolates (n=7 hospital effluent; n=4 STP influent) on
268 tigecycline-containing plates and three *K. oxytoca* isolates (n=3 hospital effluent) on
269 meropenem-containing plates. Most tigecycline-resistant *K. pneumoniae* isolates (91.7%)
270 were MDR and showed resistance against third generation cephalosporins, such as
271 cefotaxime (63.6%) and ceftazidime (63.6%) (Supplementary Table S1). None of the
272 tigecycline-resistant *K. pneumoniae* isolates were resistant to meropenem, amikacin or
273 colistin. Three presumptive *K. oxytoca* isolates obtained on meropenem-containing plates
274 showed intermediate resistance for meropenem (Supplementary Table S1).

275 276 **3.3 Genome sequence and STs of sequenced strains of *E. coli* and *Klebsiella* spp.**

277 A complete overview of the genome sequence statistics is presented in Supplementary Table
278 S2. The total length ranged from 5,857,362 bp - 6,384,740 bp and 4,590,194 bp - 5,361,939
279 bp for *Klebsiella* spp. strains and *E. coli* strains, respectively. Six *Klebsiella* spp. strains
280 which were initially identified as *K. oxytoca* by MALDI TOF MS were after sequencing re-
281 identified as either *K. michiganensis* (n=3) (K11-303, K11-314 and K11-325) or *K.*
282 *pneumoniae* (n=3) (K10-M302, K10-M304 and K10-M306) with Kleborate v.2.1.0.
283 Additionally, four *K. pneumoniae* strains (K10-T302, K10-T303, K10-T306 and K10-321)
284 were re-identified as *K. michiganensis*. A high ST diversity was observed among the
285 sequenced *E. coli* strains, including pathogenic ST131 and ST38. The most common ST
286 among the sequenced *K. pneumoniae* strains was ST307 (n=6), followed by ST2947 (n=4)
287 (Supplementary Table S2).

288 289 **3.4 Clinically important ARGs detected in *E. coli* and *Klebsiella* spp. strains**

290 Acquired ARGs conferring resistance against tetracyclines, aminoglycosides, sulfonamides
291 and quinolones were detected in sequenced *Klebsiella* spp. and *E. coli* strains (Supplementary
292 Table S3). In addition, different β -lactamase genes with *bla*_{OXA-1} (52.65%) as most dominant,

293 as well as carbapenemases, such as NDM-5 (n=3) and KPC-3 (n=3), were detected among
294 the sequenced strains. Four *K. pneumoniae* strains (K11-304, K11-305, K11-327 and K11-
295 329) with MIC of $\geq 2\mu\text{g/mL}$ for colistin carried mutations in the *mgrB* gene, contributing to a
296 truncated protein of only 24 aa instead of 47 aa long protein.

297


298 **3.5 Shotgun sequencing**

299 In total, 238 Gigabases of sequence data was generated from the shotgun metagenomic
300 sequencing of the hospital effluent samples and STP influent and STP effluent samples,
301 representing 2.1×10^{11} quality filtered reads from six samples. In the hospital effluent samples,
302 109,987 reads (0.000053% of the total reads from hospital effluent samples) matched to
303 ARGs, while 39,737 reads (0.000019% of the total reads from STP influent samples) and
304 45,069 reads (0.000022% of the total reads from STP effluent samples) matched to ARGs in
305 the STP influent and STP effluent samples, respectively. All together, these accounted for
306 between 0.064 (STP effluent from February) to 0.376 (hospital effluent from April) copies of
307 ARGs per 16S rRNA gene. We detected 676 unique ARGs in hospital effluent samples, as
308 well as 517 unique ARGs in STP influent and 567 unique ARGs in STP effluent samples,
309 respectively (Supplementary Table S4). These ARGs conferred resistance to multiple classes
310 of antibiotics, including glycolcyclines, polymyxins, glycopeptides and oxazolidinones.

311

312 **3.6 Bacterial diversity**

313 A total of 28 bacterial phyla were detected across all samples, with *Pseudomonadota* as most
314 dominant followed by *Bacillota* and *Bacteroidota* for most of the samples (Figure 1). Within
315 *Pseudomonadota*, β -proteobacteria was most dominant class followed by γ -proteobacteria
316 for most samples. At genus level, *Acinetobacter* was found to be the dominant in the majority
317 of the samples. For STP influent samples collected in February, *Bacillota* dominated
318 followed by *Pseudomonadota* and *Bacteroidota*. Within *Pseudomonadota*, β -proteobacteria
319 was most dominant class followed by γ -proteobacteria. At genus level, *Lachnospiraceae* was
320 found to be most dominant. For STP effluent samples collected in February,
321 *Pseudomonadota* dominated followed by *Bacteroidota* and *Bacillota*. Within
322 *Pseudomonadota*, β -proteobacteria was most dominant class followed by γ -proteobacteria.



323
 324 **Figure 1:** Relative abundance of bacterial diversity detected in sewage from two sampling timepoints
 325 February (Feb) and April (Apr), including hospital effluent (eff), STP influent (inf) and STP treated
 326 effluent (eff) samples. Only *Pseudomonadota* are represented at class level.

327 **3.7 Abundance of ARGs, MGEs, BMRGs and virulence genes**

328 In total, 676 unique ARGs were detected across samples. The macrolide resistance genes
 329 *msr(E)* and *mph(E)* were the most abundant ARGs in hospital effluent collected in February
 330 and April, and in STP influent and STP effluent samples collected in April. For STP influent
 331 and STP effluent collected in February, the tetracycline resistance genes *tet(Q)* and *tet(W)*
 332 were the most abundant ARGs (Figure 2). For majority of the samples, we detected genes
 333 conferring resistance to macrolides as most abundant, followed by genes conferring
 334 resistance to β-lactams and tetracyclines. Genes conferring resistance against last resort
 335 antibiotics, such as tigecycline (*tet(X)*), colistin (*mcr*), vancomycin (*van* type genes), and
 336 linezolid (*cfr(C)*) were detected across all samples (Supplementary Table S4).

337
 338 Overall, there was a higher abundance of integron-associated integrases (*intI*) and ISCR
 339 transposases in hospital effluent samples compared to STP influent and STP effluent samples.
 340 Among the studied MGEs, class 1 integrase was the most abundant followed by class 2
 341 integrase and ISCR2 for most of the samples (Supplementary Table S5).

342
 343 Several BMRGs conferring resistance to a range of compounds, such as arsenic, cobalt,
 344 copper, lead, mercury, nickel, silver, and zinc compounds were detected across samples and
 345 found in higher abundance in hospital effluent compared to STP influent and STP effluent.
 346 For all samples, the relative abundance of genes conferring resistance to mercury (*mer* genes)
 347 was higher compared to other BMRGs. A complete overview of the BMRGs is presented in
 348 Supplementary Table S6.

349

350 Virulence genes involved in adhesion factors, capsule formation, pilus formation, siderophore
351 production, and toxin productions were also detected in all samples. Important virulence
352 genes, such as aerobactin, enterobactin, yersiniabactin, salmochelin, cytotoxic necrotizing
353 factor 1, colibactin, and hemolysin, were detected across all samples (Supplementary Table
354 S7). The important virulence factor, yersiniabactin, was also detected in five (K11-302, K11-
355 304, K11-305, K11-327 and K11-329) out of 17 sequenced *K. pneumoniae* strains.

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370




Figure 2: Relative abundance of antibiotic resistance genes (ARGs) representing the 15 ARGs across samples. Hospital effluent (eff.) February (Feb) is highlighted in blue, hospital eff. April (Apr) in orange, STP influent (inf) Feb in grey, STP inf. Apr in orange, STP treated eff. Feb in blue and STP treated eff. Apr in green.

371

372 3.8 Shared ARGs across samples

373 More than 200 ARGs were shared among the samples, including genes conferring resistance
374 against last resort antibiotics, such as colistin, carbapenems, tigecycline, linezolid and
375 vancomycin. A total of 1,205 predicted gene sequences were assembled, using fARGene.
376 Several ARGs conferring resistance to aminoglycosides, macrolides, tetracyclines and
377 quinolones were shared across samples (Supplementary Table S8). Among all assembled
378 ARGs, 365 represented novel ARGs using cutoff < 90% aa identity (Table 1). The majority
379 of the predicted novel ARGs (n=244) were β -lactamases, followed by aminoglycoside
380 resistance genes (n=98) (Table 1). Among novel β -lactamases, we detected 32 novel MBLs
381 across all samples, where most of the novel MBLs were detected in the STP treated effluent
382 samples.

383

384 **Table 1:** Number of antibiotic resistance genes (ARGs) assembled using fARGene and the antibiotic
385 classes they confer resistant against.

386

Antibiotic class	Aminoglycosides			β -lactams			Macrolides			Quinolones			Tetracyclines		
	Sample	UA	KA	NA	UA	KA	NA	UA	KA	NA	UA	KA	NA	UA	KA
Hosp-eff-F	55	35	20	136	105	31	23	20	3	6	5	1	17	17	0
Hosp-eff-A	39	12	27	92	78	14	16	15	1	5	4	1	12	11	1
STP-inf-F	34	24	10	111	79	32	23	21	2	5	4	1	17	17	0
STP-inf-A	38	24	14	94	65	29	14	13	1	2	1	1	12	12	0
STP-T-eff-F	25	19	6	120	65	56	11	11	0	2	1	1	11	11	0
STP-T-eff-A	49	28	21	187	104	83	23	18	5	3	2	1	22	19	3

387 **Legend:** UA (unique ARGs); KA (known ARGs); NA (novel ARGs); Hosp (hospital); eff (effluent);
388 F (February); A (April); STP (sewage treatment plant); inf (influent); T (treated). Novel genes <90%
389 aa identity.

390

391

392

393

394 In total, 40 unique assembled ARGs were shared across all samples (Figure 3), representing
395 both novel (n=1) (belonging to class A β -lactamase) and known ARGs (n=39). A total of 54
396 unique ARGs were shared between hospital effluent and STP effluent, including three novel
397 ARGs (two β -lactamases and one ribosomal RNA methyltransferase Erm).

398

399

400


401

402

403

404

405



406
407 **Figure 3:** Venn diagram showing the shared (46, 40, 14 and 15) and exclusive (190, 274 and
408 259) antibiotic resistance genes (ARGs), including both known and novel, across the three
409 samples (hospital effluent, sewage treatment plant (STP) influent and STP treated effluent).

411 4. Discussion

412 To the best of our knowledge this is the first comprehensive study, investigating the
413 microbiota and resistome of hospital effluent and receiving STP in Norway. Although
414 resistance is low in Norway, we show high diversity of ARGs in hospital effluent and the
415 receiving STP, including genes for resistance against last resort antibiotics. We further show
416 that both novel genes and pathogenic strains are shared between the hospital effluent and STP
417 effluent (Grevskott et al., 2024). Thus, suggesting that hospital effluent is contributing to the
418 spread of AMR even in a low prevalence setting like Norway.

419
420 We detected resistance against meropenem (with a MIC of $> 16\mu\text{g/mL}$) in three out of 66
421 MDR *E. coli* isolates (4.5%) from STP influent samples (n=2) and STP effluent (n=1)
422 samples. All sequenced meropenem-resistant *E. coli* strains (11-330, 11-M301 and 11-M302)
423 carried NDM-5 and belonged to ST11681 (Supplementary Table S3). The *bla*_{NDM-5} gene was
424 located on a highly conserved region (IS30 Δ -*bla*_{NDM}-*ble*-*trpT*-IS26), which has previously
425 been observed in NDM-carrying *E. coli* strains in Norway and in Europe (Chakraborty et al.,
426 2021; Grevskott et al., 2023; Turton et al., 2022). In the clinics in Norway, the occurrence of
427 NDM-5-producing *E. coli* strains has increased during the last decade (NORM/NORM-VET,
428 2023). The spread of NDM-5 carrying *E. coli* strains in the environment through sewage may
429 have contributed to this increased detection in clinics in Norway.

430
431 The *bla*_{KPC} genes, initially described in *K. pneumoniae*, represent globally the most
432 disseminated carbapenemase genes in pathogens like *Enterobacterales* (Hansen, 2021;
433 Munoz-Price et al., 2013), *Acinetobacter* spp. and *Pseudomonas* spp. (Robledo et al., 2011).

434 Among the KPC variants, KPC-2 and KPC-3 are responsible for most epidemic outbreaks
435 worldwide (Chen et al., 2011). We detected three *bla*_{KPC-3} carrying *K. oxytoca* isolates, (K10-
436 M302, K10-M304 and K10-M306) which were later reidentified as *K. pneumoniae*, using
437 Kleborate. These stains belonged to ST307 which represents a globally disseminated high
438 risk clone (Fostervold et al., 2022; NORM/NORM-VET, 2023; Peirano et al., 2020). This ST
439 is also the most common among *K. pneumoniae* strains in clinics in Norway and is often
440 associated with carbapenemases and ESBLs (NORM/NORM-VET, 2023; Peirano et al.,
441 2020). KPC-3-producing *K. pneumoniae* belonging to ST307 have also been reported from
442 clinics in Norway (NORM/NORM-VET, 2023).

443
444 We assembled 365 novel ARGs across samples, representing 32 novel MBLs. The MBLs are
445 enzymes that confer resistance against nearly all β -lactams, including carbapenems, thus
446 limiting available treatment options (Yang et al., 2023). MBLs, such as IMP, VIM, and NDM
447 have been successfully spread among pathogens (Bakthavatchalam et al., 2016; Cornaglia et
448 al., 2011). MBLs can be divided into subclass B1 and B3 (two zinc ions) or subclass B2 (one
449 zinc ion) (Berglund et al., 2017; Palzkill, 2013). Most of the novel MBLs in our study
450 belonged to subclass B1, which also include NDM, VIM and IMP (Palzkill, 2013). These
451 were detected in the STP effluent, suggesting that these ARGs are reaching the receiving
452 environment. Presence of novel MBLs along with clinical strains may provide an opportunity
453 for pathogens to acquire these genes and this may eventually become a problem in clinics
454 (Berglund et al., 2017).

455
456 Hospital effluent has been shown to contribute to dissemination of carbapenem-resistant
457 pathogens and genes in the environment (Lamba et al., 2017). In a previous longitudinal
458 temporal study, we showed the presence of carbapenem-resistant *E. coli* strains only in the
459 STP
460 (Holen) receiving hospital sewage on different time-points (Grevskott et al., 2021; Grevskott
461 et al., 2024; Marathe et al., 2023). Further, we showed that OXA-244 carbapenemase-
462 producing *E. coli* ST38 from raw and treated sewage from STP receiving hospital effluent
463 were identical to OXA-244 carbapenemase-producing *E. coli* ST38 from clinics in Norway
464 (Grevskott et al., 2024). Although, the prevalence of resistance in clinics in Norway is low,
465 we detected a high diversity of ARGs in our study. A total of 54 unique ARGs, including
466 both known (n=51) and novel (n=3), were present in the hospital effluent and STP effluent,
467 suggesting that the genes from the hospital effluent are introduced in the environment
468 through treated sewage. Put together, our studies strongly suggest that the hospital effluent
469 contributes to the spread of epidemic-causing pathogens, carbapenemaseses as well as novel
470 ARGs into the receiving marine environment in Norway (Grevskott et al., 2024; Radisic et
471 al., 2023).

472 473 **5. Conclusions**

474 Our study shows that hospital effluent is a rich source of both known and novel ARGs,
475 although Norway has low prevalence of AMR and low usage of antibiotics. We detected *E.*
476 *coli* and *Klebsiella* spp. strains resistant to last resort antibiotics in hospital effluent as well as
477 in treated

478 effluent of the receiving plant. We further show that clinical strains carrying carbapenemases,
479 such as NDM-5 and KPC-3, are reaching the marine environment through treated sewage, in
480 Norway. We further show that the hospital effluent contributes to the spread of both known
481 and novel ARGs into the receiving environment in Norway. Our study suggests that
482 mitigation strategies, such as on-site treatment of hospital effluent or bacterial removal from
483 sewage, are needed in order to limit the ongoing dissemination of AMR into the receiving
484 environment in Norway.

485

486 **Author contributions**

487 D.H.G.: Methodology, Investigation, Formal analysis, Visualization, Writing – original draft,
488 Writing - review & editing. V.R.: Methodology, Investigation, Formal analysis,
489 Visualization, Writing - original draft, Writing - review & editing. M.P.V.: Methodology,
490 Investigation, Formal analysis, Data curation, Writing - original draft. N.P.M.:
491 Conceptualization, Methodology, Investigation, Validation, Writing - review & editing,
492 Supervision, Project administration, Funding acquisition.

493

494 **Funding**

495 The Research Council of Norway under the ResMarine project (grant number 315266)
496 funded this work.

497

498 **Acknowledgements**

499 The authors would like to thank Kristine S. Akervold (Bergen municipality), Ingvild Fenne
500 (Bergen municipality) for permission and support as well as Ole Gunnar (Bergen Vann) and
501 the people working at the STP for sewage sample collection.

502

503 **Conflicts of Interest**

504 None.

505

506 **References**

- 507 Alcock, B. P., Raphenya, A. R., Lau, T. T., Tsang, K. K., Bouchard, M., Edalatmand, A., Huynh,
508 W., Nguyen, A.-L. V., Cheng, A. A., Liu, S., Min, S. Y., Miroshnichenko, A., Tran, H.-
509 K., Werfalli, R. E., Nasir, J. A., Oloni, M., Speicher, D. J., Florescu, A., Singh, B.,...
510 McArthur, A. G. (2020). CARD 2020: antibiotic resistance surveillance with the
511 comprehensive antibiotic resistance database. *Nucleic acids research*, 48(D1), D517-D525.
512 <https://doi.org/10.1093/nar/gkz935>
- 513 Bakthavatchalam, Y. D., Anandan, S., & Veeraraghavan, B. (2016). Laboratory detection and clinical
514 implication of oxacillinase-48 like carbapenemase: the hidden threat. *Journal of global*
515 *infectious diseases*, 8(1), 41. <https://doi.org/10.4103/0974-777X.176149>
- 516 Bengtsson-Palme, J., Hartmann, M., Eriksson, K. M., Pal, C., Thorell, K., Larsson, D. G. J., &
517 Nilsson, R. H. (2015). METAXA2: improved identification and taxonomic classification of
518 small and large subunit rRNA in metagenomic data. *Molecular ecology resources*, 15(6),
519 1403-1414. <https://doi.org/10.1111/1755-0998.12399>
- 520 Berglund, F., Marathe, N. P., Österlund, T., Bengtsson-Palme, J., Kotsakis, S., Flach, C.-F., Larsson,
521 D. J., & Kristiansson, E. (2017). Identification of 76 novel B1 metallo- β -lactamases through
522 large-scale screening of genomic and metagenomic data. *Microbiome*, 5, 1-13.
523 <https://doi.org/10.1186/s40168-017-0353-8>

- 524 Berglund, F., Österlund, T., Boulund, F., Marathe, N. P., Larsson, D. J., & Kristiansson, E. (2019).
525 Identification and reconstruction of novel antibiotic resistance genes from metagenomes.
526 *Microbiome*, 7, 1-14. <https://doi.org/10.1186/s40168-019-0670-1>
- 527 Bonnin, R. A., Jousset, A. B., Emeraud, C., Oueslati, S., Dortet, L., & Naas, T. (2021). Genetic
528 diversity, biochemical properties, and detection methods of minor carbapenemases in
529 *Enterobacterales*. *Frontiers in Medicine*, 7, 616490.
530 <https://doi.org/10.3389/fmed.2020.616490>
- 531 Bortolaia, V., Kaas, R. S., Ruppe, E., Roberts, M. C., Schwarz, S., Cattoir, V., Philippon, A., Allesoe,
532 R. L., Rebelo, A. R., Florensa, A. F., Fagelhauer, L., Chakraborty, T., Neumann, B., Werner,
533 G., Bender, J. K., Stingl, K., Nguyen, M., Coppens, J., Xavier, B. B.,... Aarestrup, F. M.
534 (2020). ResFinder 4.0 for predictions of phenotypes from genotypes. *Journal of*
535 *Antimicrobial Chemotherapy*, 75(12), 3491-3500. <https://doi.org/10.1093/jac/dkaa345>
- 536 Boyd, S. E., Livermore, D. M., Hooper, D. C., & Hope, W. W. (2020). Metallo- β -lactamases:
537 structure, function, epidemiology, treatment options, and the development pipeline.
538 *Antimicrobial Agents and Chemotherapy*, 64(10), 00397-00320.
539 <https://doi.org/10.1128/AAC.00397-20>
- 540 Carattoli, A., Zankari, E., García-Fernández, A., Voldby Larsen, M., Lund, O., Villa, L., Møller
541 Aarestrup, F., & Hasman, H. (2014). In silico detection and typing of plasmids using
542 PlasmidFinder and plasmid multilocus sequence typing. *Antimicrobial Agents and*
543 *Chemotherapy*, 58(7), 3895-3903. <https://doi.org/10.1128/aac.02412-14>
- 544 Chakraborty, T., Sadek, M., Yao, Y., Imirzalioglu, C., Stephan, R., Poirer, L., & Nordmann, P. (2021).
545 Cross-border emergence of *Escherichia coli* producing the carbapenemase NDM-5 in
546 Switzerland and Germany. *Journal of Clinical Microbiology*, 59(3), 02238-02220.
547 <https://doi.org/10.1128/jcm.02238-20>
- 548 Chen, L., Mediavilla, J. R., Endimiani, A., Rosenthal, M. E., Zhao, Y., Bonomo, R. A., & Kreiswirth,
549 B. N. (2011). Multiplex real-time PCR assay for detection and classification of *Klebsiella*
550 *pneumoniae* carbapenemase gene (*bla_{KPC}*) variants. *Journal of Clinical Microbiology*, 49(2),
551 579-585. <https://doi.org/10.1128/jcm.01588-10>
- 552 Chen, L., Zheng, D., Liu, B., Yang, J., & Jin, Q. (2016). VFDB 2016: hierarchical and refined dataset
553 for big data analysis - 10 years on. *Nucleic acids research*, 44(D1), D694-D697.
554 <https://doi.org/10.1093/nar/gkv1239>
- 555 Cornaglia, G., Giamarellou, H., & Rossolini, G. M. (2011). Metallo- β -lactamases: a last frontier for β -
556 lactams? *The Lancet infectious diseases*, 11(5), 381-393. [https://doi.org/10.1016/S1473-3099\(11\)70056-1](https://doi.org/10.1016/S1473-3099(11)70056-1)
- 558 Deguenon, E., Dognon, V., Houssou, V. M. C., Gbotche, E., Ahoyo, R. A., Fabiyi, K., Agbankpe, J.,
559 Mousse, W., Lougbegnon, C., & Klotoe, J. R. (2022). Hospital effluents as sources of
560 antibiotics residues, resistant bacteria and heavy metals in Benin. *SN Applied Sciences*, 4(8),
561 206. <https://doi.org/10.1007/s42452-022-05095-9>
- 562 EUCAST. (2023). Breakpoint tables for interpretation of MICs and zone diameters Version 13.1.
563 European Committee on Antimicrobial Susceptibility Testing (EUCAST).
564 [https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/
565 v_13.1_Breakpoint_Tables.pdf](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_13.1_Breakpoint_Tables.pdf)
- 566 Fostervold, A., Hetland, M. A., Bakksjø, R., Bernhoff, E., Holt, K. E., Samuelsen, Ø., Simonsen, G.
567 S., Sundsfjord, A., Wyres, K. L., & Löhr, I. H. (2022). A nationwide genomic study of clinical
568 *Klebsiella pneumoniae* in Norway 2001–15: introduction and spread of ESBLs facilitated by
569 clonal groups CG15 and CG307. *Journal of Antimicrobial Chemotherapy*, 77(3), 665-674.
570 <https://doi.org/10.1093/jac/dkab463>
- 571 Grevskott, D. H., Ghavidel, F. Z., Svanevik, C. S., & Marathe, N. P. (2021). Resistance profiles and
572 diversity of β -lactamases in *Escherichia coli* strains isolated from city-scale sewage
573 surveillance in Bergen, Norway mimic clinical prevalence. *Ecotoxicology and environmental*
574 *safety*, 226, 112788. <https://doi.org/10.1016/j.ecoenv.2021.112788>
- 575 Grevskott, D. H., Radisic, V., Salvà-Serra, F., Moore, E. R., Akervold, K. S., Victor, M. P., & Marathe,
576 N. P. (2024). Emergence and dissemination of epidemic-causing OXA-244 carbapenemase-
577 producing *Escherichia coli* ST38 through hospital sewage in Norway, 2020–2022. *Journal of*
578 *Hospital infection*. <https://doi.org/10.1016/j.jhin.2023.12.020>

- 579 Grevskott, D. H., Salvà-Serra, F., Moore, E. R., & Marathe, N. P. (2020). Nanopore sequencing
580 reveals genomic map of CTX-M-type extended-spectrum β -lactamases carried by
581 *Escherichia coli* strains isolated from blue mussels (*Mytilus edulis*) in Norway. *BMC*
582 *Microbiology*, 20(1), 1-10. <https://doi.org/10.1186/s12866-020-01821-8>
- 583 Grevskott, D. H., Salvà-Serra, F., Moore, E. R., & Marathe, N. P. (2023). Complete sequence of a new
584 conjugative multidrug-resistance encoding IncFII/IncFIA/IncFIB plasmid carrying NDM-6
585 metallo- β -lactamase from pathogenic *Escherichia coli* sequence type 167 isolated from
586 sewage in Norway. *Journal of Global Antimicrobial Resistance*, 33, 291-293.
587 <https://doi.org/10.1016/j.jgar.2023.04.005>
- 588 Gupta, S. K., Padmanabhan, B. R., Diene, S. M., Lopez-Rojas, R., Kempf, M., Landraud, L., &
589 Rolain, J.-M. (2014). ARG-ANNOT, a new bioinformatic tool to discover antibiotic
590 resistance genes in bacterial genomes. *Antimicrobial Agents and Chemotherapy*, 58(1), 212-
591 220. <https://doi.org/10.1128/aac.01310-13>
- 592 Hansen, G. T. (2021). Continuous evolution: perspective on the epidemiology of carbapenemase
593 resistance among *Enterobacteriales* and other Gram-negative bacteria. *Infectious diseases and*
594 *therapy*, 10, 75-92. <https://doi.org/10.1007/s40121-020-00395-2>
- 595 Inda-Díaz, J. S., Lund, D., Parras-Moltó, M., Johnning, A., Bengtsson-Palme, J., & Kristiansson, E.
596 (2023). Latent antibiotic resistance genes are abundant, diverse, and mobile in human, animal,
597 and environmental microbiomes. *Microbiome*, 11(1), 1-16. <https://doi.org/10.1186/s40168-023-01479-0>
- 598 Karkman, A., Pärnänen, K., & Larsson, D. J. (2019). Fecal pollution can explain antibiotic resistance
599 gene abundances in anthropogenically impacted environments. *Nature communications*,
600 10(1), 80. <https://doi.org/10.1038/s41467-018-07992-3>
- 601 Khan, M. T., Shah, I. A., Ihsanullah, I., Naushad, M., Ali, S., Shah, S. H. A., & Mohammad, A. W.
602 (2021). Hospital wastewater as a source of environmental contamination: An overview of
603 management practices, environmental risks, and treatment processes. *Journal of Water*
604 *Process Engineering*, 41, 101990. <https://doi.org/10.1016/j.jwpe.2021.101990>
- 605 Lam, M. M., Wick, R. R., Watts, S. C., Cerdeira, L. T., Wyres, K. L., & Holt, K. E. (2021). A genomic
606 surveillance framework and genotyping tool for *Klebsiella pneumoniae* and its related species
607 complex. *Nature communications*, 12(1), 4188. <https://doi.org/10.1038/s41467-021-24448-3>
- 608 Lamba, M., Graham, D. W., & Ahammad, S. (2017). Hospital wastewater releases of carbapenem-
609 resistance pathogens and genes in urban India. *Environmental Science & Technology*, 51(23),
610 13906-13912. <https://doi.org/10.1021/acs.est.7b03380>
- 611 Logan, L. K., & Bonomo, R. A. (2016). Metallo- β -lactamase (MBL)-producing *Enterobacteriaceae* in
612 United States children. *Open Forum Infectious Diseases*, 3(2), ofw090.
613 <https://doi.org/10.1093/ofid/ofw090>
- 614 Marathe, N. P., Berglund, F., Razavi, M., Pal, C., Dröge, J., Samant, S., Kristiansson, E., & Larsson,
615 D. J. (2019). Sewage effluent from an Indian hospital harbors novel carbapenemases and
616 integron-borne antibiotic resistance genes. *Microbiome*, 7, 1-11.
617 <https://doi.org/10.1186/s40168-019-0710-x>
- 618 Marathe, N. P., Radisic, V., Salvà-Serra, F., Moore, E. R., & Grevskott, D. H. (2023). Emergence of
619 new IncHI2 multidrug-resistance plasmids carrying VIM-1 metallo- β -lactamase in
620 *Escherichia coli* in Norway. *The Lancet Microbe*, 4(9), E663-E664.
621 [https://doi.org/10.1016/S2666-5247\(22\)00389-5](https://doi.org/10.1016/S2666-5247(22)00389-5)
- 622 Munoz-Price, L. S., Poirel, L., Bonomo, R. A., Schwaber, M. J., Daikos, G. L., Cormican, M.,
623 Cornaglia, G., Garau, J., Gniadkowski, M., & Hayden, M. K. (2013). Clinical epidemiology
624 of the global expansion of *Klebsiella pneumoniae* carbapenemases. *The Lancet infectious*
625 *diseases*, 13(9), 785-796. [https://doi.org/10.1016/S1473-3099\(13\)70190-7](https://doi.org/10.1016/S1473-3099(13)70190-7)
- 626 NORM/NORM-VET. (2023). *Usage of Antimicrobial Agents and Occurrence of Antimicrobial*
627 *Resistance in Norway 2022*. Norwegian monitoring programme on antimicrobial resistance in
628 bacteria from humans, food, feed and animals (NORM/NORM-VET).
629 <https://www.vetinst.no/en/surveillance-programmes/norm-norm-vet-report>
- 630 Orias, F., & Perrodin, Y. (2013). Characterisation of the ecotoxicity of hospital effluents: a review.
631 *Science of the Total Environment*, 454, 250-276.
632 <https://doi.org/10.1016/j.scitotenv.2013.02.064>
- 633

- 634 Pal, C., Bengtsson-Palme, J., Rensing, C., Kristiansson, E., & Larsson, D. J. (2014). BacMet:
635 antibacterial biocide and metal resistance genes database. *Nucleic acids research*, 42(D1),
636 D737-D743. <https://doi.org/10.1093/nar/gkt1252>
- 637 Palzkill, T. (2013). Metallo- β -lactamase structure and function. *Annals of the New York Academy of*
638 *Sciences*, 1277(1), 91-104. <https://doi.org/10.1111/j.1749-6632.2012.06796.x>
- 639 Pärnänen, K., Karkman, A., Hultman, J., Lyra, C., Bengtsson-Palme, J., Larsson, D. J., Rautava, S.,
640 Isolauri, E., Salminen, S., & Kumar, H. (2018). Maternal gut and breast milk microbiota
641 affect infant gut antibiotic resistance and mobile genetic elements. *Nature communications*,
642 9(1), 3891. <https://doi.org/10.1038/s41467-018-06393-w>
- 643 Peirano, G., Chen, L., Kreiswirth, B. N., & Pitout, J. D. (2020). Emerging antimicrobial-resistant
644 high-risk *Klebsiella pneumoniae* clones ST307 and ST147. *Antimicrobial Agents and*
645 *Chemotherapy*, 64(10), 01148-01120. <https://doi.org/10.1128/aac.01148-20>
- 646 Radisic, V., Grevskott, D. H., Lunestad, B. T., Øvreås, L., & Marathe, N. P. (2023). Sewage-based
647 surveillance shows presence of *Klebsiella pneumoniae* resistant against last resort antibiotics
648 in the population in Bergen, Norway. *International Journal of Hygiene and Environmental*
649 *Health*, 248, 114075. <https://doi.org/https://doi.org/10.1016/j.ijheh.2022.114075>
- 650 Radisic, V., Nimje, P. S., Bienfait, A. M., & Marathe, N. P. (2020). Marine plastics from Norwegian
651 west coast carry potentially virulent fish pathogens and opportunistic human pathogens
652 harboring new variants of antibiotic resistance genes. *Microorganisms*, 8(8), 1200.
653 <https://doi.org/10.3390/microorganisms8081200>
- 654 Robledo, I. E., Aquino, E. E., & Vázquez, G. J. (2011). Detection of the KPC gene in *Escherichia*
655 *coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, and *Acinetobacter baumannii* during
656 a PCR-based nosocomial surveillance study in Puerto Rico. *Antimicrobial Agents and*
657 *Chemotherapy*, 55(6), 2968-2970. <https://doi.org/10.1128/AAC.01633-10>
- 658 Sheu, C.-C., Chang, Y.-T., Lin, S.-Y., Chen, Y.-H., & Hsueh, P.-R. (2019). Infections caused by
659 carbapenem-resistant *Enterobacteriaceae*: an update on therapeutic options. *Frontiers in*
660 *Microbiology*, 10, 80. <https://doi.org/10.3389/fmicb.2019.00080>
- 661 Stalder, T., Barraud, O., Casellas, M., Dagot, C., & Ploy, M.-C. (2012). Integron involvement in
662 environmental spread of antibiotic resistance. *Frontiers in Microbiology*, 3, 119.
663 <https://doi.org/10.3389/fmicb.2012.00119>
- 664 Tamma, P. D., & Simner, P. J. (2018). Phenotypic detection of carbapenemase-producing organisms
665 from clinical isolates. *Journal of Clinical Microbiology*, 56(11), 01140-01118.
666 <https://doi.org/10.1128/jcm.01140-18>
- 667 Tatusova, T., DiCuccio, M., Badretdin, A., Chetvernin, V., Nawrocki, E. P., Zaslavsky, L., Lomsadze,
668 A., Pruitt, K. D., Borodovsky, M., & Ostell, J. (2016). NCBI prokaryotic genome annotation
669 pipeline. *Nucleic acids research*, 44(14), 6614-6624. <https://doi.org/10.1093/nar/gkw569>
- 670 Turton, J. F., Pike, R., Perry, C., Jenkins, C., Turton, J. A., Meunier, D., & Hopkins, K. L. (2022).
671 Wide distribution of *Escherichia coli* carrying IncF plasmids containing bla NDM-5 and *rmtB*
672 resistance genes from hospitalized patients in England. *Journal of medical microbiology*,
673 71(8), 001569. <https://doi.org/10.1099/jmm.0.001569>
- 674 van Duin, D., & Doi, Y. (2017). The global epidemiology of carbapenemase-producing
675 *Enterobacteriaceae*. *Virulence*, 8(4), 460-469.
676 <https://doi.org/10.1080/21505594.2016.1222343>
- 677 VKM. (2020). *Assessment of the impact of wastewater and sewage sludge treatment methods on*
678 *antimicrobial resistance. Scientific opinion of the Panel on Microbial Ecology of the*
679 *Norwegian Scientific Committee for Food and Environment*. (VKM 2020: 08). Norwegian
680 Scientific Committee for Food and Environment (VKM) [https://nmbu.brage.unit.no/nmbu-](https://nmbu.brage.unit.no/nmbu-xmlui/bitstream/handle/11250/2829018/)
681 [xmlui/bitstream/handle/11250/2829018/](https://nmbu.brage.unit.no/nmbu-xmlui/bitstream/handle/11250/2829018/)
682 [Assessment+of+the+impact+of+wastewater+and+sewage+sludge+treatment+methods+on+an](https://nmbu.brage.unit.no/nmbu-xmlui/bitstream/handle/11250/2829018/Assessment+of+the+impact+of+wastewater+and+sewage+sludge+treatment+methods+on+an+timicrobial+resistance+-01.10.2020.pdf?sequence=2)
683 [timicrobial+resistance+-01.10.2020.pdf?sequence=2](https://nmbu.brage.unit.no/nmbu-xmlui/bitstream/handle/11250/2829018/Assessment+of+the+impact+of+wastewater+and+sewage+sludge+treatment+methods+on+an+timicrobial+resistance+-01.10.2020.pdf?sequence=2)
- 684 WHO. (2017, February 27). *WHO publishes list of bacteria for which new antibiotics are urgently*
685 *needed*. World Health Organization (WHO). [https://www.who.int/news/item/27-02-2017-](https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed)
686 [who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed](https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed)

687 Yang, Y., Yan, Y.-H., Schofield, C. J., McNally, A., Zong, Z., & Li, G.-B. (2023). Metallo- β -
688 lactamase-mediated antimicrobial resistance and progress in inhibitor discovery. *Trends in*
689 *microbiology*, 31(7), 735-748. <https://doi.org/10.1016/j.tim.2023.01.013>

690 Zhu, J., Li, Q., Li, X., Kang, J., Song, Y., Song, J., Yin, D., & Duan, J. (2020). Successful control of
691 the first carbapenem-resistant *Klebsiella pneumoniae* outbreak in a Chinese hospital 2017–
692 2019. *Antimicrobial Resistance & Infection Control*, 9(1), 91. [https://doi.org/10.1186/s13756-](https://doi.org/10.1186/s13756-020-00757-y)
693 020-00757-y

694
695
696

697 **Supplementary Materials**

698 **Supplementary Table S1:** Minimum inhibitory concentrations (MICs) of *Escherichia coli*
699 (n= 66) and *Klebsiella* spp. (n=55) strains in this study.

700 **Supplementary Table S2:** Genome assembly statistics of sequenced strains (n=36) in this
701 study.

702 **Supplementary Table S3:** Detected antibiotic resistance genes (ARGs) and sequence types
703 (STs) in sequenced strains (n=36).

704 **Supplementary Table S4:** Detected antibiotic resistance genes (ARGs) across six samples.

705 **Supplementary Table S5:** Relative abundance of most detected mobile genetic elements
706 (MGEs) across samples.

707 **Supplementary Table S6:** Detected biocide/metal resistance genes (BMRGs) across all
708 samples.

709 **Supplementary Table S7:** Detected virulence genes across all samples.

710 **Supplementary Table S8:** Assembled known and novel antibiotic resistance genes (ARGs)
711 across all samples.

712